Synthesis and acrosin inhibitory activities of 5-phenyl-1H-pyrazole-3-carboxylic acid amide derivatives

A series of novel 5-phenyl-1H-pyrazole-3-carboxylic acid amide derivatives were designed, synthesized, and their acrosin inhibitory activities in vitro were evaluated. The results of the acrosin inhibitory activity showed that all target compounds were more potent than control TLCK. Compounds AQ-A1, AQ-D3, AQ-D4, AQ-E4 and AQ-E5 exhibited stronger acrosin inhibitory activities than control ISO-1. Especially, compound AQ-E5 displayed the most potent acrosin inhibitory activity in all the compounds, with an IC₅₀ of 0.01 μmol/mL. This study provided a new structural class for the development of novel acrosin inhibitory agents.     

Discovery of natural estrogen receptor modulators with structure-based virtual screening

Eleven compounds were identified as estrogen receptor modulators from an in-house natural product database (NPD) by structure-based virtual screening for ERα and ERβ. Among them, 3 compounds were confirmed as ER agonists and 8 compounds were confirmed as ER antagonists by yeast two-hybrid (Y2H) assay, with EC₅₀ values ranging from several micromolar to 100 micromolar. In this study, a novel series of cycloartane triterpenoids isolated from Schisandra glaucescens Diels was found to have ER antagonistic effect, the most potent antagonist of which exhibited activity with EC₅₀ value of 2.55 and 4.68 μM for ERα and ERβ, respectively. Moreover, the types of modulation and subtype selectivity were also investigated through molecular docking simulation.     

Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson’s disease

In Parkinson’s disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson’s disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson’s disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure–activity relationship study revealed that the piperidino group was the best choice for the R¹ amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC₅₀ values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound 1n with the thiazolopyridine core structure showed the most potent activity with the IC₅₀ value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives.     

GIV: A Tool for Genomic Islands Visualization

A Genomic Islands (GI) is a chunk of DNA sequence in a genome whose origin can be traced back to other organisms or viruses. The detection of GIs plays an indispensable role in biomedical research, due to the fact that GIs are highly related to special functionalities such as disease-causing GIs - pathogenicity islands. It is also very important to visualize genomic islands, as well as the supporting features corresponding to the genomic islands in the genome. We have developed a program, Genomic Island Visualization (GIV), which displays the locations of genomic islands in a genome, as well as the corresponding supportive feature information for GIs. GIV was implemented in C++, and was compiled and executed on Linux/Unix operating systems.

Availability

GIV is freely available for non-commercial use at http://www5.esu.edu/cpsc/bioinfo/software/GIV     

海南特有种东方琼楠种群结构特征

为探讨海南特有种东方琼楠(Beilschmiedia tungfangensis)种群结构特征,在海南尖峰岭林区设置20.4hm2样地,从种群径级结构、静态生命表、存活曲线、空间分布格局等方面进行分析。结果表明:1)东方琼楠种群径级分布呈倒"J"型,为增长型种群;2)在第Ⅲ级(DBH:10～15cm)时生命期望值最高,向大龄级和小龄级呈递减趋势;3)存活曲线接近DeeveyⅢ型,呈凹型;死亡率曲线和消失率曲线呈"V"型;4)不同分析方法均表明该种群呈聚集分布,且聚群强度较大;5)聚块性指数随径级呈"正余弦"变化。     

马尾松花粉醇提物降脂作用与预防肥胖的实验研究

本实验通过观察马尾松花粉醇提物对小鼠脂质代谢的影响来探讨其抑制肥胖的初步机制.实验采用随机分组对照方法,对不同组的小鼠进行不同的干预处理.实验结果显示与高脂组(FC)组相比3个醇提物组在终体重、体重净增加和体重增加率方面都有明显降低(P＜0.01);体脂含量也有不同程度降低但未出现显著性差异;血脂中总胆固醇(TC)水平有不同程度的降低,并且甘油三酯(TG)都有明显降低(P＜0.01),高密度脂蛋白胆固醇(HDLC)水平都有显著性升高(P＜0.01);瘦素(LEP)和脂联素(ADP)水平都有不同程度升高;肝脏和脂肪组织中的肉碱棕榈酰转移酶(CPT-I)酶含量水平都得到显著升高(P＜0.01).上述结果证明马尾松花粉醇提物可以明显控制小鼠的体重增长以及改善体内脂质代谢水平,证明松花粉醇提物在抑制肥胖方面具有重要作用.     

人源EFA6A蛋白Sec7结构域的克隆表达与纯化

作为小GTP酶Arf6的鸟甘酸交换因子(GEF),人EFA6A蛋白主要包含PH和Sec7两个结构域,Sec7是行使GEF功能的核心区域。通过分析Jpred、Uniprot等生物信息学软件的预测结果,从全长1 024 aa中选取的重组Sec7结构域的边界为506-719,共214 aa。以人脑cDNA文库为模板,通过优化PCR程序成功扩增出Sec7基因,经NdeI和XhoI双酶切后亚克隆至原核表达载体p28a中,成功构建p28-Sec7重组子,测序结果与NCBI中公布的序列100%吻合。将重组质粒p28-Sec7转化至BL21-Gold(DE3)宿主菌中,终浓度0.3 mmol/L IPTG、16℃、24 h诱导表达,重组蛋白经过Ni柱和分子筛两步纯化。试验结果显示,重组Sec7成功表达,性质均一,纯度高于95%,表达量为70 mg/L。